natgillin/translations-raw huggingface dataset:
Amlodipine exhibits linear pharmacokinetics between the therapeutic dose range of 5 mg and 10 mg.
Farmakokinetiki amlodipina v okviru odmerjanja med 5 mg in 10 mg je linearna.
Amlodipine has been safely administered with digoxin, warfarin, atorvastatin, sildenafil, anti-acid medicinal products (aluminium hydroxide, magnesium hydroxide, simeticone), cimetidine, antibiotics and oral hypoglycaemic medicinal products.
Uporaba amlodipina je bila varna v kombinaciji z digoksinom, varfarinom, atorvastatinom, s sildenafilom, z antacidi (aluminijevim hidroksidom, magnezijevem hidroksidom, simetikonom), s cimetidinom, z antibiotiki in peroralnimi hipoglikemiki.
Amlodipine is a ‘calcium channel blocker’.
Amlodipin je zaviralec kalcijevih kanalčkov.
Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.
Amlodipin se v jetrih v veliki meri (približno 90 %) presnovi v neaktivne presnovke.
amlodipine, bepridil, diltiazem, felodipine, nicardipine, nifedipine, nisoldipine or verapamil (when taken by mouth)
amlodipin, bepridil, diltiazem, felodipin, nikardipin, nifedipin, nisoldipin ali verapamil (če zdravilo zaužijete)
amlodipine, digoxin, diltiazem, disopyramide, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nicardipine, nifedipine, propafenone, timolol and verapamil, medicines used to treat heart problems
amlodipin, digoksin, diltiazem, dizopiramid, felodipin, flekainid, lidokain, metoprolol, meksiletin, nikardipin, nifedipin, propafenon, timolol in verapamil; zdravila, ki se uporabljajo za zdravljenje bolezni srca
Amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (for heart disease) as the therapeutic effect or side effects of these medicines may be increased.
amlodipin, diltiazem, dizopiramid, karvedilol, felodipin, flekainid, metoprolol, meksiletin, nifedipin, nikardipin, propafenon, timolol, verapamil (za bolezni srca), ker se lahko zvečajo terapevtski ali neželeni učinki teh zdravil.
amlodipine, diltiazem, felodipine,
o amlodipin, diltiazem, felodipin,
amlodipine, diltiazem, felodipine, nicardipine, nifedipine, medicines used to treat high blood pressure and heart problems
amlodipin, diltiazem, felodipin, nikardipin, nifedipin, zdravila, ki se uporabljajo za zdravljenje visokega krvnega tlaka ali težav s srcem
amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nisoldipine, verapamil
amlodipin, diltiazem, felodipin, nikardipin, nifedipin, nisoldipin, verapamil
amlodipine, felodipine, nifedipine, nicardipine, digoxin, diltiazem - used for high blood pressure and some heart problems. quetiapine – used for some mental illnesses such as schizophrenia, bipolar disorder and major depressive disorder
amlodipin, felodipin, nifedipin, nikardipin, digoksin, diltiazem - za zvišan krvni tlak in določene okvare srca kvetiapin – uporablja se za zdravljenje nekaterih duševnih bolezni, kot so shizofrenija, bipolarna motnja in huda depresivna motnja.
Amlodipine, one of the active substances in Rasilamlo, may make you feel dizzy and drowsy.
Amlodipin, ki je ena od zdravilnih učinkovin v zdravilu Rasilamlo, lahko povzroča omotičnost in zaspanost.
Amlodipine-Valsartan Mylan
EU/1/16/1092/010
Amlodipine-Valsartan Mylan
EU/1/16/1092/032
Amlodipine/valsartan has not been studied in any patient population other than hypertension.
Amlodipin/valsartan nista raziskana pri nobeni drugi populaciji, razen pri bolnikih s hipertenzijo.
Amlodipine/valsartan is contraindicated in patients with severe hepatic impairment (see section 4.3).
Pri bolnikih s hudo okvaro jeter je kominacija amlodipina/valsartana kontraindicirana (glejte poglavje 4.3).
Amlodipine/Valsartan Mylan 10 mg/160 mg
Amlodipin/valsartan Mylan 10 mg/160 mg
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Tablet core:
Amlodipin/valsartan Mylan 10 mg/160 mg filmsko obložene tablete Jedro tablete
Amlodipine/Valsartan Mylan 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Amlodipine/Valsartan Mylan 5 mg/160 mg.
Zdravilo Amlodipin/valsartan Mylan 10 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno nadzorovan samo z 10 mg amlodipina ali s 160 mg valsartana ali z jemanjem zdravila Amlodipin/valsartan Mylan 5 mg/160 mg.
Amlodipine/Valsartan Mylan 10 mg/160 mg tablets are light brown, oval, biconvex film-coated tablet marked with “AV3” on one side and “M” on the other side.
Tablete zdravila Amlodipin/valsartan 10 mg/160 mg so svetlo rjave, ovalne, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV3'' na eni strani in ''M'' na drugi strani.
Amlodipine/Valsartan Mylan 5 mg/160 mg
Amlodipin/valsartan Mylan 5 mg/160 mg
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Tablet core:
Amlodipin/valsartan Mylan 5 mg/160 mg filmsko obložene tablete Jedro tablete
Amlodipine/Valsartan Mylan 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
Zdravilo Amlodipin/valsartan Mylan 5 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno nadzorovan samo s 5 mg amlodipina ali s 160 mg valsartana
Amlodipine/Valsartan Mylan 5 mg/160 mg tablets are yellow, oval, biconvex film-coated tablet marked with “AV2” on one side and “M” on the other side.
Tablete zdravila Amlodipin/valsartan 5 mg/160 mg so rumene, ovalne, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV2'' na eni strani in ''M'' na drugi strani.
Amlodipine/Valsartan Mylan 5 mg/80 mg
Amlodipin/valsartan Mylan 5 mg/80 mg
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Tablet core:
Amlodipin/valsartan Mylan 5 mg/80 mg filmsko obložene tablete Jedro tablete
Amlodipine/Valsartan Mylan 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Zdravilo Amlodipin/valsartan Mylan 5 mg/80 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno nadzorovan samo s 5 mg amlodipina ali z 80 mg valsartana
Amlodipine/Valsartan Mylan 5 mg/80 mg tablets are light yellow, round, biconvex film-coated tablet marked with “AV1” on one side and “M” on the other side.
Tablete zdravila Amlodipin/valsartan 5 mg/80 mg so svetlo rumene, okrogle, bikonveksne filmsko obložene tablete z vtisnjeno oznako ''AV1'' na eni strani in ''M'' na drugi strani.
Amlodipine/Valsartan Mylan and older people (age 65 years or over)
Zdravilo Amlodipin/valsartan Mylan in starejši ljudje (stari 65 let ali več)
Amlodipine/Valsartan Mylan can be used with or without food.
Bolnik lahko zdravilo Amlodipin/valsartan Mylan vzame s hrano ali brez nje.
Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Zdravilo Amlodipin/valsartan Mylan je indicirano pri odraslih, pri katerih krvni tlak ni ustrezno urejen ob monoterpiji z amlodipinom in valsartanom.
Amlodipine/Valsartan Mylan with food and drink
Zdravilo Amlodipin/valsartan Mylan skupaj s hrano in pijačo
Amlodipine/valsartan/hydrochlorothiazide
Amlodipin/valsarta/hidroklorotiazid
amlopidine, ranolazine – used to treat angina pectoris
amlopidin, ranolazin – uporablja se za zdravljenje angine pektoris
AMMONAPS 500 mg tablets
AMMONAPS 500 mg tablete
AMMONAPS 940 mg/g granules. sodium phenylbutyrate
AMMONAPS 940 mg/g zrnca natrijev fenilbutirat
AMMONAPS does not completely prevent the occurrence of an acute excess of ammonia in the blood and is not appropriate for treating such a condition, which is a medical emergency.
Zdravilo AMMONAPS ne prepreči pojava odvečnih količin amonijaka v krvi popolnoma in ni primeren za zdravljenje takšnega stanja, ki je medicinsko nujen primer.
AMMONAPS granules contain 124 mg (5.4 mmol) of sodium per gram of sodium phenylbutyrate, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose.
Zdravilo AMMONAPS zrnca vsebuje 124 mg (5,4 mmol) natrija na gram natrijevega fenilbutirata, kar ustreza 2,5 g (108 mmol) natrija v maksimalnem dnevnem odmerku natrijevega fenilbutirata, ki znaša 20 g.
AMMONAPS must be combined with a diet reduced in proteins, designed especially for you by the doctor and the dietician.
Zdravilo AMMONAPS se mora kombinirati s prehrano z zmanjšano vsebnostjo beljakovin, ki jo je vaš zdravnik ali dietetik prilagodil posebej za vas.
AMMONAPS should therefore be used with caution in patients with congestive heart failure or severe renal insufficiency, and in clinical conditions where there is sodium retention with oedema.
Pri predpisovanju zdravila AMMONAPS bolnikom s kongestivno odpovedjo srca, s hudimi motnjami v delovanju ledvic ali kliničnimi stanji, kjer se pojavlja zadrževanje natrija z edemi, je zato potrebna previdnost.
AMMONAPS tablets should not be used in patients with dysphagia due to the potential risk of oesophageal ulceration if tablets are not promptly delivered to the stomach.
Zaradi možne nevarnosti, da bi nastala ulceracija požiralnika, če tablete ne bi takoj prispele v želodec, zdravilo AMMONAPS pri bolnikih z disfagijo ni dovoljeno uporabljati.
Ammonaps was authorised under ‘Exceptional Circumstances’, because, as the disease is rare, limited information was available at the time of approval.
Zdravilo Ammonaps je bilo sprva odobreno v „izjemnih okoliščinah“, saj so bile zaradi redkosti bolezni ob odobritvi dovoljenja na voljo le omejene informacije.
Ammonia is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma.
Amoniak je še posebno toksičen za možgane in v hudih primerih povzroči zmanjšano zavest in komo.
Ammonia which is produced as described above by the bacterial hydrolysis is included into the metabolism as NH +.
Amonijak, ki nastane z bakterijsko hidrolizo (kot je opisano zgoraj), se vključi v presnovo v obliki NH4+.
Amnesia
amnezija koma
amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
amnezija (izguba spomina), oslabljen spomin (pozabljivost), poslabšana koordinacija/ataksija (motena usklajenost mišičnih gibov), parestezija (mravljinčenje), motnje pozornosti (izguba koncentracije)
amnesia (loss of memory),memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
amnezija (izguba spomina), oslabljen spomin (pozabljivost), poslabšana koordinacija/ataksija (motena usklajenost mišičnih gibov), parestezija (mravljinčenje), motnje pozornosti (izguba koncentracije)
Amnesia (memory disturbance)
amnezija (moten spomin)
Amnesia (memory disturbance)
amnezija (moten spomin),
Amnesia (memory disturbance)*
amnezija (moten spomin)*,
Amnesia 9
Amnezija9 Disartrija
Amnesia 9
z okulogiracijo)11
Amnesia Aphasia
amnezija1,
Amnesia Coma
amnezija koma
Amnesia, agitation, confusion, somnolence, nervousness.
amnezija, vznemirjenost, zmedenost, zaspanost, živčnost
amnesia, carpal tunnel syndrome, cognitive disorder, disturbance in attention, dizziness postural, dysgeusia, hypersomnia, hypoaesthesia, lethargy, memory impairment, migraine, neuropathy peripheral, paraesthesia, somnolence, tension headache, tremor, poor quality sleep
amnezija, sindrom karpalnega kanala, kognitivna motnja, motnje pozornosti, posturalna omotica, motnje okušanja, hipersomnija, hipestezija, letargija, motnje spomina, migrena, periferna nevropatija, parestezija, zaspanost, tenzijski glavobol, tremor, slaba kakovost spanja
amnesia, carpal tunnel syndrome, cognitive disorder, disturbance in attention, dizziness postural, dysgeusia, hypersomnia, hypoaesthesia, lethargy, memory impairment, migraine, neuropathy peripheral, paraesthesia, somnolence, tension headache, tremor, poor quality sleep
amnezija, sindrom karpalnega kanala, kognitivne motnje, motnje pozornosti, posturalna omotica, motnje okušanja, hipersomnija, hipestezija, letargija, motnje spomina, migrena, periferna nevropatija, parestezija, zaspanost, tenzijski glavobol, tremor, slaba kakovost spanca
Amnesia, dementia Alzheimer’s type, dizziness postural, dysgeusia, epilepsy, hydrocephalus, hypogeusia, memory impairment, migraine, migraine with aura, motor neurone disease, nerve compression, paresis, presyncope, sciatica, vascular headache
amnezija, demenca Alzheimerjevega tipa, položajna omotica, disgevzija, epilepsija, vodenoglavost, hipogevzija, spominske motnje, migrena, migrena z avro, amiotrofična lateralna skleroza, kompresija živca, pareza, presinkopa, išias, vaskularni glavobol
Amnesia, dysarthria, dysgeusia, balance disorder, tremor
amnezija, disartrija, disgevzija, motnje ravnotežja, tremor
amnesia, hyperkinesia, sudden onset of sleep, syncope
amnezija, hiperkinezija, nenaden nepremagljiv spanec, sinkopa
amnesia, hyperkinesia, sudden onset of sleep, syncope
prenajedanje1, kompulzivno nakupovanje, blodnje, hiperfagija1, hiperseksualnost, motnje libida, paranoja, patološko hazardiranje, nemir, delirij
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
amnezija, oslabljen spomin, poslabšana koordinacija/ataksija,
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
amnezija, oslabljen spomin, poslabšana koordinacija/ataksija, parestezija, motnje pozornosti
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia,disturbance in attention
amnezija, oslabljen spomin, poslabšana koordinacija/ataksija, parestezija, motnje pozornosti
Amnesia, memory impairment, syncope, migraine, ataxia, paraesthaesia, dysphonia, taste loss, hypoaesthesia, hyperaesthesia, hypertonia, somnolence, disturbance in attention, tremor, dysgeusia
amnezija, motnje spomina, sinkopa, migrena, ataksija, parestezija, disfonija, izguba okusa, hipoestezija, hiperestezija, hipertonija, somnolenca, motnje pozornosti, tremor, disgevzija
amnesia, paraesthesia, somnolence ataxia/coordination abnormal, dizziness, disturbance in attention, parosmia, speech disorder (dysarthria, slurred speech), hypoaesthesia
amnezija, parestezije, zaspanost ataksija/nekoordiniranost gibov, vrtoglavica zmanjšana koncentracija, parosmija; motnje govora (dizartrija, nerazločno izgovarjanje); hipoestezija
amnesia, paraesthesia, somnolence ataxia/coordination abnormal, dizziness, disturbance in attention, parosmia, speech disorder (dysarthria, slurred speech), hypoaesthesia
amnezija, parestezije, zaspanost ataksija/nekoordiniranost gibov, vrtoglavica, zmanjšana koncentracija, parosmija; motnje govora (dizartrija, nerazločno izgovarjanje); hipoestezija
amnesia1, dyskinesia, hyperkinesia1, sudden onset of sleep, syncope
amnezija, diskinezija, hiperkinezija, nenaden nepremagljiv spanec, sinkopa
amnesia1, dyskinesia, hyperkinesia1, sudden onset of sleep, syncope
amnezija1, diskinezija, hiperkinezija1, nenaden nepremagljiv spanec, sinkopa
Amnesia9 Dysarthria
Amnezija9 Disartrija
amodiaquine and chloroquine (used to treat malaria and some forms of inflamamtion),
amodiakvin in klorokvin (uporabljata se za zdravljenje malarije in nekaterih oblik vnetja),
Among
6.
Among 1,968 treatment-experienced patients receiving PREZISTA co-administered with ritonavir 600/100 mg twice daily, 236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis (see section 4.4).
Med 1.968 bolniki, ki so že bili zdravljeni s protiretrovirusnimi zdravili in so prejemali zdravilo PREZISTA skupaj z ritonavirjem (600/100 mg dvakrat na dan), jih je bilo 236 okuženih tudi s hepatitisom B ali C. Pri bolnikih s sočasno okužbo je povišanje koncentracij jetrnih transaminaz bolj verjetno (pred zdravljenjem in kot posledica zdravljenja), kot pri bolnikih, ki nimajo kroničnega virusnega hepatitisa (glejte poglavje 4.4).
Among 128 patients who discontinued nivolumab in combination with ipilimumab due to adverse reaction, median PFS was 16.7 months (95% CI: 10.2, NA), and the ORR was 69% (88/128) with 15% (19/128) achieving a complete response.
Pri 128 bolnikih, pri katerih je bilo zdravljenje z nivolumabom v kombinaciji z ipilimumabom zaradi neželenih učinkov prekinjeno, je mediana PFS znašala 16,7 meseca (95 % interval zaupanja: 10,2; NP), delež celokupnega odziva (ORR) pa je znašal 69 % (88/128), s popolnim odzivom pri 15 % (19/128) bolnikov.
Among 159 subjects randomised to Simponi 50 mg + MTX, 96 were still on this treatment at week 104.
Med 159 preiskovanci, ki so bili naključno razvrščeni v skupino, ki je prejemala zdravilo Simponi 50 mg z metotreksatom, jih je bilo v 104. tednu 96 še vedno na tem zdravljenju.
Among 31 treatment-naïve adult patients treated with velaglucerase alfa, the mean lumbar spine BMD Z-score at baseline was -1.820 (95% CI: -2.21, -1.43) and increased by 0.62 (95% CI: 0.39, 0.84) from baseline following 24 months of treatment with velaglucerase alfa.
Med 31 še nezdravljenimi odraslimi bolniki, ki so dobivali velaglucerazo alfa, je bila srednja Z-vrednost mineralne gostote kosti (BMD) ledvenega dela hrbtenice ob izhodišču - 1,820 (95-odstotni IZ: -2,21; -1,43) in se je po 24 mesecih zdravljenja z velaglucerazo alfa povečala za 0,62 (95-odstotni IZ: 0,39; 0,84) glede na izhodišče.
Among 497 patients initially randomized to apremilast 30 mg twice daily, 375 (75%) patients were still on this treatment on Week 52.
Med 497 bolniki, ki so bili v začetku randomizirani na apremilast 30 mg dvakrat na dan, se je 375 (75 %) bolnikov v 52. tednu še vedno zdravilo.
Among 69 hypophosphatasia patients enrolled in the clinical trials and who have post baseline data, 56 (81.2%) tested positive for anti-drug antibodies at some time point after receiving Strensiq treatment.
Med 69 bolniki s hipofosfatazijo, vključenimi v klinična preskušanja, pri katerih obstajajo podatki po izhodišču, je pri 56 (81,2 %) test pokazal, da so bili v eni časovni točki po zdravljenju z zdravilom Strensiq pozitivni za protitelesa proti zdravilu.
Among 7 patients with preexisting cirrhosis and/or portal hypertension who received lumacaftor/ivacaftor in the placebo-controlled, Phase 3 studies, worsening liver function with increased ALT, AST, bilirubin, and hepatic encephalopathy was observed in one patient.
Med 7 bolniki z obstoječo cirozo in/ali portalno hipertenzijo, ki so prejemali lumakaftor/ivakaftor v študijah 3. faze, kontroliranih s placebom, so pri enem bolniku opazili slabšanje funkcije jeter z zvišanimi ALT, AST, bilirubinom in hepatično encefalopatijo.
Among 898 hypertensive patients who received various doses of irbesartan/hydrochlorothiazide (range: 37.5 mg/6.25 mg to 300 mg/25 mg) in placebo-controlled trials, 29.5% of the patients experienced adverse reactions.
Med 898 bolniki s hipertenzijo, ki so v s placebom nadzorovanih študijah prejemali različne odmerke kombinacije irbesartan/hidroklortiazid (razpon: 37,5 mg/6,25 mg do 300 mg/25 mg), je 29,5 % bolnikov izkusilo neželene učinke.
Among 9 boys with left ventricular mass (LVMI) indexed to height2.7 within the normal range for children (<39 g/m2.7 in boys) at baseline, LVMI remained stable at levels below the left ventricular hypertrophy (LVH) threshold throughout the 6.5 years of treatment.
Pri 9 dečkih, ki so ob izhodišču imeli maso levega prekata (LVMI), indeksirano na telesno višino2.7, v normalnem razponu za otroke (< 39 g/m2.7 pri dečkih), je LVMI ostala stabilna na ravni pod pragom hipertrofije levega prekata v celotnem 6,5-letnem obdobju zdravljenja.
Among age and body-size related covariates tested, age was a significant covariate on apparent clearance of sunitinib (the younger the age of the paediatric patient, the lower the apparent clearance).
Med testiranimi sospremenljivkami, povezanimi s starostjo in velikostjo telesa, je bila starost pomembna sospremenljivka navideznega očistka sunitiniba (nižja kot je bila starost pediatričnega bolnika, manjši je bil navidezni očistek).
Among all patients treated in clinical trials (including both those with severe neutropenia and those who did not develop severe neutropenia), 11 % (4 % of courses) developed fever and 26 % (9 % of courses) developed infection.
11 % vseh bolnikov (4 % ciklov zdravljenja), ki so se zdravili v kliničnih raziskavah (vključno z bolniki s hudo nevtropenijo in s tistimi, pri katerih se nevtropenija ni pojavila), je imelo zvišano telesno temperaturo, pri 26 % (9 % ciklov zdravljenja) pa so se pojavile okužbe.
Among all patients treated in clinical trials (including both those with severe neutropenia and those who did not develop severe neutropenia), 11 % (4 % of courses) developed fever and 26 % (9 % of courses) developed infection.
Med vsemi bolniki, ki so jih zdravili v kliničnih preskušanjih (vključno s tistimi, ki so imeli hudo nevtropenijo, in tistimi, pri katerih se huda nevtropenija ni pojavila) jih je imelo 11 % (4 % ciklusov zdravljenja) zvišano telesno temperaturo in 26 % (9 % ciklusov zdravljenja) okužbe.
Among all randomised and treated patients, the median change from baseline in CD4+ cell count at the last measurement up to Week 48 was +23 cells/mm3 in patients receiving tipranavir with ritonavir (N=740) versus +4 cells/mm3 in the comparator PI/ritonavir (N=727) arm.
Med vsemi naključno izbranimi in zdravljenimi bolniki je bila srednja sprememba števila celic CD4+ glede na izhodiščno vrednost ob zadnji meritvi do 48. tedna +23 celic/mm3 pri bolnikih, ki so prejemali tipranavir ob ritonavirju (n = 740), proti +4 celic/mm3 pri bolnikih v primerjalni skupini z zaviralcem proteaze ob ritonavirju (n = 727).
Among all ZYPADHERA treated patients, sedation was reported by 4.7% of patients.
Med vsemi bolniki, zdravljenimi z zdravilom ZYPADHERA, so o sedaciji poročali pri 4,7 % bolnikov.
Among Bexsero recipients, 5849 were infants and children (less than 2 years of age), 250 were children (2 to 10 years of age) and 2677 were adolescents and adults.
Med prejemniki cepiva Bexsero je bilo 5849 dojenčkov in otrok (starih do 2 let), 250 otrok (starih od 2 do 10 let) ter 2677 mladostnikov in odraslih oseb.
Among children and adolescents, treated with Ribavirin in combination with interferon alfa- 2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% versus 1%) during treatment and during the 6-month follow-up after treatment.
Pri otrocih in mladostnikih zdravljenih z ribavirinom v kombinaciji z interferonom alfa-2b, so pogosteje poročali o samomorilnih mislih ali poskusu samomora kot pri odraslih (2,4 % v primerjavi z 1 %) med zdravljenjem in v času 6-mesečnega spremljanja bolnikov po zdravljenju.
Among children and adolescents, treated with Ribavirin Teva Pharma B.V. in combination with interferon alfa-2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % versus 1 %) during treatment and during the 6-month follow-up after treatment.
Pri otrocih in mladostnikih zdravljenih z zdravilom Ribavirin Teva Pharma B.V. v kombinaciji z interferonom alfa-2b, so pogosteje poročali o samomorilnih mislih ali poskusu samomora kot pri odraslih (2,4 % v primerjavi z 1 %) med zdravljenjem in v času 6-mesečnega spremljanja bolnikov po zdravljenju.